- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
CEA-Scan MoAb agent cleared in Europe
Immunomedics of Morris Plains, NJ, last week announced that ithas received clearance from the European Commission to marketits CEA-Scan colorectal cancer imaging agent in the 15 countriesof the European Union. The monoclonal-antibody-based agent
Immunomedics of Morris Plains, NJ, last week announced that it
has received clearance from the European Commission to market
its CEA-Scan colorectal cancer imaging agent in the 15 countries
of the European Union. The monoclonal-antibody-based agent received
U.S. clearance in June (SCAN 7/17/96). Mallinckrodt Medical of
St. Louis has marketing rights to CEA-Scan in both the U.S. and
Europe.
MRI-Based AI Radiomics Model Offers 'Robust' Prediction of Perineural Invasion in Prostate Cancer
July 26th 2024A model that combines MRI-based deep learning radiomics and clinical factors demonstrated an 84.8 percent ROC AUC and a 92.6 percent precision-recall AUC for predicting perineural invasion in prostate cancer cases.
Breast MRI Study Examines Common Factors with False Negatives and False Positives
July 24th 2024The absence of ipsilateral breast hypervascularity is three times more likely to be associated with false-negative findings on breast MRI and non-mass enhancement lesions have a 4.5-fold likelihood of being linked to false-positive results, according to new research.
Can Polyenergetic Reconstruction Help Resolve Streak Artifacts in Photon Counting CT?
July 22nd 2024New research looking at photon-counting computed tomography (PCCT) demonstrated significantly reduced variation and tracheal air density attenuation with polyenergetic reconstruction in contrast to monoenergetic reconstruction on chest CT.
